BTIG Research restated their buy rating on shares of Compass Pathways (NASDAQ:CMPS – Free Report) in a report published on Tuesday morning, MarketBeat.com reports. The firm currently has a $25.00 target price on the stock.
Several other analysts also recently weighed in on the stock. Compass Point set a $25.00 price target on shares of Compass Pathways in a research note on Tuesday, July 7th. Stifel Nicolaus increased their price objective on Compass Pathways from $14.00 to $21.00 and gave the stock a “buy” rating in a research note on Tuesday, July 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Compass Pathways in a research note on Thursday, October 15th. Evercore upgraded Compass Pathways from an “in-line” rating to an “outperform” rating and set a $21.00 price objective on the stock in a report on Wednesday, July 8th. Finally, Wall Street Zen lowered Compass Pathways from a “sell” rating to a “strong sell” rating in a research report on Saturday, October 31st. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Compass Pathways currently has a consensus rating of “Moderate Buy” and a consensus price target of $23.14.
Read Our Latest Stock Analysis on Compass Pathways
Compass Pathways Trading Down 9.2%
CMPS stock opened at $7.81 on Tuesday. Compass Pathways has a 12 month low of $4.88 and a 12 month high of $15.87. The firm’s 50-day moving average is $12.44 and its 200 day moving average is $10.40. The company has a market capitalization of $1.08 billion, a PE ratio of -2.24 and a beta of 2.43. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.50 and a quick ratio of 1.30.
Compass Pathways (NASDAQ:CMPS – Get Free Report) last released its quarterly earnings data on Tuesday, November 3rd. The company reported ($0.31) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.08. On average, research analysts anticipate that Compass Pathways will post -0.92 EPS for the current year.
Institutional Inflows and Outflows
A number of institutional investors have recently added to or reduced their stakes in the business. North Star Investment Management Corp. lifted its holdings in Compass Pathways by 23.9% during the third quarter. North Star Investment Management Corp. now owns 9,317 shares of the company’s stock worth $116,000 after buying an additional 1,800 shares during the period. EverSource Wealth Advisors LLC increased its holdings in shares of Compass Pathways by 67.7% in the 1st quarter. EverSource Wealth Advisors LLC now owns 4,754 shares of the company’s stock valued at $26,000 after acquiring an additional 1,920 shares during the period. WINTON GROUP Ltd increased its holdings in shares of Compass Pathways by 20.1% in the 2nd quarter. WINTON GROUP Ltd now owns 17,900 shares of the company’s stock valued at $253,000 after acquiring an additional 3,000 shares during the period. Ancora Advisors LLC bought a new position in shares of Compass Pathways in the 2nd quarter worth $43,000. Finally, China Universal Asset Management Co. Ltd. raised its position in shares of Compass Pathways by 15.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 24,432 shares of the company’s stock worth $317,000 after acquiring an additional 3,249 shares in the last quarter. Hedge funds and other institutional investors own 46.19% of the company’s stock.
Compass Pathways Company Profile
Compass Pathways plc is a biotechnology company developing novel treatments for mental health conditions. The company’s lead investigational product is COMP360, a proprietary formulation of synthetic psilocybin administered with psychological support in a controlled clinical setting.
Compass Pathways has focused primarily on treatment-resistant depression, a condition in which patients do not respond adequately to existing therapies. Its research programs have included mid- and late-stage clinical trials designed to evaluate the safety and effectiveness of COMP360, as well as studies exploring its potential use in other mental health disorders.
Founded in 2016 and headquartered in London, Compass Pathways conducts research and clinical development activities across the United States, the United Kingdom and other international markets.
Featured Stories
- Five stocks we like better than Compass Pathways
- Google’s Credit Backstop May Be TeraWulf’s Biggest Advantage
- Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to Watch
- Qualcomm Beat Earnings, But Its Fastest-Growing Businesses Have a Catch
- Oil, Uranium, or Renewables? 3 Energy Plays for a Changing Market
Receive News & Ratings for Compass Pathways Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compass Pathways and related companies with MarketBeat.com's FREE daily email newsletter.
